Article
Oncology
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzalez Farre, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Summary: The DESTINY-Breast01 study evaluated the efficacy of trastuzumab deruxtecan in heavily pretreated HER2-positive metastatic breast cancer patients, and found that it showed durable clinical activity in patients with treated brain metastases.
Article
Oncology
Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xiao Hong Chen, Kirsten B. Goldberg, Yutao Gong, William F. Pierce, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Summary: Tucatinib in combination with trastuzumab and capecitabine was approved by the FDA for the treatment of advanced HER2-positive breast cancer, with demonstrated efficacy in patients with brain metastases. The approval was based on data from the HER2CLIMB trial showing significant benefit in progression-free survival and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Thibaut Sanglier, Jinjoo Shim, Neil Lamarre, Claudia Pena-Murillo, Vincent Antao, Filippo Montemurro
Summary: This study compared the effectiveness of T-DM1 and LC in the treatment of HER2-positive breast cancer patients with brain metastases. The results showed that T-DM1 was more effective than LC in the real world and had better clinical significance compared to LC.
Review
Oncology
Daniele Galanti, Alessandro Inno, Maria La Vecchia, Nicolo Borsellino, Lorena Incorvaia, Antonio Russo, Stefania Gori
Summary: Brain metastases are often associated with HER2+ breast cancer, and systemic therapy with trastuzumab has been the mainstay. Other HER2-targeted agents have been introduced in clinical practice, with newer agents such as neratinib, tucatinib, and trastuzumab deruxtecan showing interesting activity against brain metastases. Further research is needed to elucidate the optimal sequence of these agents and their combination with local treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, Erika Hamilton, Amelia Zelnak, Louis Fehrenbacher, Erik Jakobsen, Elsa Curtit, Frances Boyle, Eva Harder Brix, Andrew Brenner, Laurence Crouzet, Cristiano Ferrario, Montserrat Munoz-Mateu, Hendrik-Tobias Arkenau, Nayyer Iqbal, Sramila Aithal, Margaret Block, Soeren Cold, Mathilde Cancel, Olwen Hahn, Teja Poosarla, Erica Stringer-Reasor, Marco Colleoni, David Cameron, Giuseppe Curigliano, Muriel Siadak, Kendra DeBusk, Jorge Ramos, Wentao Feng, Karen Gelmon
Summary: The study showed that tucatinib added to trastuzumab and capecitabine significantly improved health-related quality of life (HR-QoL) for HER2+ metastatic breast cancer patients. Patients with brain metastases saw longer maintenance of HR-QoL with tucatinib therapy compared to those without it.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Min-long Chen, Wenjie Yu, Binbin Cui, Yijian Yu, Zhaosheng Ma
Summary: This article reports a case of a female patient with HER2-positive metastatic breast cancer and brain metastases who received pyrotinib and trastuzumab-based systematic therapy after palliative craniocerebral radiotherapy as first-line treatment. During the treatment, the tumor lesions regressed significantly, and chemotherapy drugs were gradually phased out. The patient continued to receive trastuzumab and pyrotinib for HER2-targeted therapy, achieving more than 26 months of progression-free survival with stable disease. Further clinical trials are needed to verify the potential of radiotherapy followed by dual HER2-targeted therapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Review
Oncology
Alejandro Garcia-Alvarez, Andri Papakonstantinou, Mafalda Oliveira
Summary: Development of brain metastases is a significant event for patients with breast cancer, particularly those with HER2-positive tumors. Advances in targeted therapy against the HER2 receptor have improved management of HER2-positive breast cancer. Despite these improvements, brain metastases continue to be a challenge, highlighting the need for further research and innovative treatment strategies.
Article
Oncology
Vaseem M. Khatri, Matthew N. Mills, Daniel E. Oliver, Hsiang-Hsuan Michael Yu, Michael A. Vogelbaum, Peter A. Forsyth, Hatem H. Soliman, Hyo S. Han, Kamran A. Ahmed
Summary: This retrospective analysis investigated the safety and effectiveness of stereotactic radiosurgery (SRS) combined with tucatinib in treating HER2-positive breast cancer brain metastases. The results suggest that SRS combined with tucatinib, capecitabine, and trastuzumab appears to be a safe and feasible treatment for HER2-positive brain metastases.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Review
Oncology
Inge M. Werter, Sharon Remmelzwaal, George L. Burchell, Tanja D. de Gruijl, Inge R. Konings, Hans J. van der Vliet, C. Willemien Menke-van der Houven Van Oordt
Summary: This study aimed to investigate the impact of different systemic therapies on patients with HER2-positive metastatic breast cancer and brain metastases. The most effective treatments appeared to be Tucatinib and trastuzumab-deruxtecan, while pyrotinib might be suitable for Asian patients.
Article
Medicine, General & Internal
Xiaoping Ma, Yan Li, Li Li, Chunyan Gao, Dan Liu, Hongyu Li, Zhenhui Zhao, Bing Zhao
Summary: The study explored effective methods through combining pyrotinib to treat brain metastasis with HER2-positive advanced breast cancer. Pyrotinib-based combination therapy was found to be safe and efficient for treating HER2-positive brain metastasis, with pyrotinib combined with nab-paclitaxel showing superior efficacy.
ANNALS OF MEDICINE
(2022)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Peter A. Kaufman, Edward Neuberger, Naomi R. M. Schwartz, Shu Wang, Yutong Liu, Ling- Hsu, Karen Bartley, Matthew T. Blahna, Brian T. Pittner, Gabriel Wong, Carey Anders
Summary: This study describes patient characteristics, treatment patterns, and clinical outcomes of tucatinib treatment in the real-world setting. The results show that tucatinib is effective in the 2L/3L setting and has similar outcomes to the pivotal HER2CLIMB trial. These findings highlight the importance of earlier use of tucatinib in HER2+ MBC.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Review
Oncology
Kreina Sharela Vega Cano, David Humberto Marmolejo Castaneda, Santiago Escriva-de-Romani, Cristina Saura
Summary: Therapeutic advances have significantly improved the natural history of HER2-positive metastatic breast cancer. Double anti-HER2 blockade with a taxane is currently the best option in first-line, but T-DXd has emerged as the new standard in second-line. New treatments and combinations are being developed to address resistance and progress in these patients.
Article
Oncology
Giuseppe Curigliano, Geoffrey Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Summary: This study evaluated the efficacy and safety of gedatolisib in combination with other anti-tumour agents in advanced solid tumours. The results showed that the combination therapy of gedatolisib and cisplatin had good clinical activity and acceptable tolerability profile in patients with triple-negative breast cancer, both in first-line and second/third-line settings.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Karin Jordan, Evandro De Azambuja, Teresa Amaral, Michiel Strijbos, Giuseppe Curigliano, Florian Lordick
Summary: High-quality medical oncology education is crucial for medical oncologists to provide excellent care for cancer patients. The demand for such education is increasing due to the development of new therapies and the rising number of cancer patients. Access to medical oncology education varies across countries. The European Society for Medical Oncology and other associations have implemented initiatives, such as the ESMO/ASCO global curriculum, to promote access to high-quality education.
ONCOLOGY RESEARCH AND TREATMENT
(2023)
Article
Computer Science, Information Systems
Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li
Summary: Cancer subtyping provides valuable insights and is an essential step toward personalized medicine. However, recent studies have highlighted inconsistencies in breast cancer subtype classifications, indicating the need for optimization. We propose a deep-learning-based algorithm, Moanna, that integrates multi-omics data to predict breast cancer subtypes. Evaluation results show high accuracy and improved correlation with patient survival compared to existing methods.
Article
Oncology
Nancy U. Lin, Rashmi K. Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L. Bedard, Virginia Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara A. Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
Summary: This study evaluated the efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with ERBB2-positive MBC and BMs. The results showed that this treatment option improved overall survival and reduced the risk of developing new brain lesions, indicating its importance for these patients.
Article
Oncology
Balaji Virassamy, Franco Caramia, Peter Savas, Sneha Sant, Jianan Wang, Susan N. Christo, Ann Byrne, Kylie Clarke, Emmaline Brown, Zhi Ling Teo, Bianca von Scheidt, David Freestone, Luke C. Gandolfo, Karsten Weber, Julia Teply-Szymanski, Ran Li, Stephen J. Luen, Carsten Denkert, Sibylle Loibl, Olivia Lucas, Charles Swanton, Terence P. Speed, Phillip K. Darcy, Paul J. Neeson, Laura K. Mackay, Sherene Loi
Summary: CD8+ tumor-infiltrating lymphocytes with a tissue-resident memory T (TRM) cell phenotype are associated with favorable prognosis in triple-negative breast cancer (TNBC). The study shows that intratumoral CD8+ T cells in mice and TNBC patients transcriptionally resemble each other. Two intratumoral sub-populations were identified, one with markers of terminal exhaustion (TEX-like) and the other with a bona fide resident phenotype (TRM-like). Treatment with checkpoint inhibitors resulted in expansion of the TRM-like subset with enhanced cytotoxic capacity and improved clinical outcomes in TNBC patients.
Review
Oncology
Julia Dixon-Douglas, Sherene Loi
Summary: Recently, adding PD-1 pathway targeting immune checkpoint inhibitors (ICI) to neoadjuvant chemotherapy has been shown to improve outcomes for early-stage triple-negative breast cancer (TNBC) patients. However, the use of ICI carries the risk of immune-related toxicities and there is currently no predictive biomarker to select patients who will benefit the most. It is suggested that all node positive patients should receive ICI, while lower-risk TNBC patients with strong pre-existing immune activation may benefit from ICI combined with less cytotoxic chemotherapy. The impact of adjuvant ICI and other therapies in non-responders requires further investigation.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano
Summary: Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer with unfavorable outcomes, traditionally had limited systemic treatment options. However, novel drugs have been approved and are causing economic challenges due to their high prices.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Review
Oncology
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Summary: This is a summary of an article about a study called P-REALITY X, which found that patients with metastatic HR+/HER2- breast cancer treated with palbociclib plus an AI lived longer than those treated with an AI only in routine clinical practice. These results support the use of palbociclib plus an AI as the standard first-line treatment for this type of breast cancer.
Editorial Material
Oncology
Elena Geuna, Giuseppe Curigliano, Filippo Montemurro
Article
Oncology
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Summary: This study evaluates whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations for ER+/HER2- early-stage breast cancers. The study found that using Oncotype DX significantly reduces discordance and uncertainty among oncologists, and improves agreement in adjuvant chemotherapy recommendations for patients.
Article
Oncology
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat
Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.
Review
Biochemistry & Molecular Biology
Laura Gilardi, Lighea Simona Airo Farulla, Giuseppe Curigliano, Giovanni Corso, Maria Cristina Leonardi, Francesco Ceci
Summary: Invasive lobular cancer (ILC) is the second most common histological type of breast cancer, characterized by infiltrative growth and metastatic spread. FDG-PET/CT is widely used in oncology and breast cancer patient evaluation, but its efficacy in ILCs is considered suboptimal. This review aims to summarize the current literature on the use of FDG-PET/CT in ILC and discuss the potential of non-FDG radiotracers for precision medicine.
Review
Public, Environmental & Occupational Health
Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent
Summary: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, has shown improved outcomes for patients with HER2-positive and HER2-low metastatic breast cancer. Monitoring and managing T-DXd-related adverse events (AEs) is a growing need, and experts from the Asia-Pacific region provided recommendations based on clinical trial evidence and regional healthcare considerations. Proactive monitoring and management are crucial for maximizing the benefits of T-DXd.
Article
Oncology
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belen Perez-Mies, Rodrigo Sanchez-Bayona, Luis Manso, Mario Martinez, Ana Garrido-Garcia, Rosario Serrano-Pardo, Ramon Colomer, Miguel Quintela-Fandino
Summary: This study evaluated the immune microenvironment in TNBC tumors and found that the infiltration of TILs and the profiling of lymphocytes varied in tumors with hyperactivation of P70S6K. Decreased CD20(+) cells and CD8(+)/CD4(+) ratio were observed in high p-P70S6K tumors. The p-P70S6K score was positively correlated with CD4(+) and Foxp3(+) T cells, while it was negatively correlated with CD8(+)/CD4(+) and CD8(+)/Foxp3(+) ratios.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Mattia Rediti, David Venet, Andrea Joaquin Garcia, Dominique Agbor-Tarh, Marion Maetens, Delphine Vincent, Samira Majjaj, Sarra El-Abed, Takayuki Ueno, Serena Di Cosimo, Martine Piccart, Lajos Pusztai, Sherene Loi, Roberto Salgado, Giuseppe Viale, Francoise Rothe, Christos Sotiriou